Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Image-tracking technology helps scientists study nature v. nurture in neural stem cells

  • Babies benefit from parenting classes even before birth

  • Emotional behavior altered after multiple exposures to anesthesia during infancy

  • Diabetes and brain tangles may be linked independently of Alzheimer's disease

  • Do antipsychotic medications affect cortical thinning?

  • Reward, aversion behaviors activated through same brain pathways

  • Risk of cognitive impairment in children born prematurely may be predicted using MRI after birth

  • Researchers develop a likely new combo treatment for the deadliest form of brain cancer

  • Accuracy of dementia brain imaging must improve

  • Magnetic stimulation effective in helping Parkinson's patients walk

  •